Ropes & Gray represented the underwriters in Rhythm Pharmaceuticals’ (Nasdaq: RYTM) $201 million equity offering, including the full exercise of the underwriters’ $26 million option to purchase additional shares. The transaction closed on July 11.
Rhythm is a global commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases.
The team was led by capital markets partners Tom Danielski and Tristan VanDeventer.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
